本文へスキップ

(社)東京血液疾患研究所(MRC JAPAN)は、国際MDS財団に認定されたCenter of Excellenceです。

MRC JAPANは世界最先端の
骨髄異形成症候群(MDS)の研究機関です。

新掲論文・学会発表Papers&Presentation

本年の実績(論文・執筆)

2014年
Yamamoto Y, Kawashima A, Kashiwagi E, Ogata K.
A Jehovah's Witness with acute myeloid leukemia (AML) successfully treated with an epigenetic drug, azacitidine: A clue for development of anti-AML therapy requiring minimum blood transfusions. (Submitted)
2014年
Porwit A, van de Loosdrecht AA, Bettelheim P, Brodersen LE, Burbury K, Cremers E, Della Porta MG, Ireland R, Johansson U, Matarraz S, Ogata K, Orfao A, Preijers F, Psarra K, Subira D, Valent P, van der Velden VH, Wells D, Westers TM, Kern W, Bene MC.
Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS.
Leukemia 2014 (in press)
2014年
Della Porta MG, Picone C, Tenore A, Yokose N, Malcovati L, Cazzola M, Ogata K.
Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia.
Haematologica 2014 99:e8-10
2013年8月号
Okuyama N, Sperr WR, Kadar K, Bakker S, Szombath G, Handa H, Tamura H,Kondo A, Valent P, Várkonyi J, van de Loosdrecht A, Ogata K.
Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: A multicenter retrospective study.
Leuk Res. 2013 37:862-7.
2013年7月号
Ueda Y, Mizutani C, Nannya Y, Kurokawa M, Kobayashi S, Takeuchi J, Tamura H, Ogata K, Dan K, Shibayama H, Kanakura Y, Niimi K, Sasaki K, Watanabe M, Emi N, Teramura M, Motoji T, Kida M, Usuki K, Takada S, Sakura T, Ito Y, Ohyashiki K, Ogawa H, Suzuki T, Ozawa K, Imai K, Kasai M, Hata T, Miyazaki Y, Morita Y, Kanamaru A, Matsuda A, Tohyama K, Koga D, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F.
Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
Leuk Lymphoma. 2013 54:1450-8.
2013年3月号
van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subirá D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VH, Wells DA, de Witte TM, Zettl F, Béné MC, Westers TM.
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.
Leuk Lymphoma. 2013 54:472-5.
2013年2月号
Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, Hyodo H, Shinya E, Takahashi H, Dong H, Tamada K, Chen L, Dan K, Ogata K.
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.
Leukemia. 2013 47;464-472.

本年の実績(学会発表)


The 12th international Symposium on Myelodysplastic Syndromes. May 8-13, 2013. Berlin, Germany

  • CD7 expression on MDS blasts is associated with apoptosis resistance with decreased levels of the apoptosis-related protein Bad. N. Okuyama, H. Tamura, N. Kamei, M. Ishibashi, Y. Hamada, A. Kondo, K. Moriya, K. Ogata
  • Clinical significance of the interleukin-2 receptor alpha-chain expressed by blasts in myelodysplastic syndromes M. Ishibashi, H. Tamura, K. Ogata      
  • Flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group T.M. Westers, W. Kern, R. Ireland, M.C. Béné, M.G. Della Porta, K. Ogata, A.A. Van de Loosdrecht

今までの実績(論文・学会発表・執筆)


論文


1. 欧文原著


2. 欧文症例報告・総説


3. 和文原著・症例報告・総説



分担執筆


4. 欧文/和文


学会発表


5. 国外学会発表(抜粋)


6. 国内学会発表(抜粋)

  

Supported by

Supported by

(社)東京血液疾患研究所
(MRC JAPAN)

〒182-0001
東京都調布市緑ヶ丘1-45-46
        クレナイビル3F
TEL 03-6750-1017
FAX 03-6750-1013

E-mail : info@MRCJAPAN.com